188 related articles for article (PubMed ID: 14662732)
1. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.
Costa B; Colleoni M; Conti S; Trovato AE; Bianchi M; Sotgiu ML; Giagnoni G
Br J Pharmacol; 2004 Jan; 141(1):4-8. PubMed ID: 14662732
[TBL] [Abstract][Full Text] [Related]
2. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
Pascual D; Goicoechea C; Suardíaz M; Martín MI
Pain; 2005 Nov; 118(1-2):23-34. PubMed ID: 16213089
[TBL] [Abstract][Full Text] [Related]
3. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Guindon J; Desroches J; Dani M; Beaulieu P
Eur J Pharmacol; 2007 Jul; 568(1-3):173-6. PubMed ID: 17555742
[TBL] [Abstract][Full Text] [Related]
4. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Bridges D; Ahmad K; Rice AS
Br J Pharmacol; 2001 Jun; 133(4):586-94. PubMed ID: 11399676
[TBL] [Abstract][Full Text] [Related]
5. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
[TBL] [Abstract][Full Text] [Related]
6. Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model.
Linsell O; Brownjohn PW; Nehoff H; Greish K; Ashton JC
J Drug Target; 2015 May; 23(4):353-9. PubMed ID: 25541465
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
8. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms.
Johanek LM; Heitmiller DR; Turner M; Nader N; Hodges J; Simone DA
Pain; 2001 Sep; 93(3):303-315. PubMed ID: 11514089
[TBL] [Abstract][Full Text] [Related]
10. Antihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats.
Hama AT; Urban MO
Neurosci Lett; 2004 Mar; 358(1):21-4. PubMed ID: 15016425
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
12. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Liang YC; Huang CC; Hsu KS
Neuropharmacology; 2007 Jul; 53(1):169-77. PubMed ID: 17572451
[TBL] [Abstract][Full Text] [Related]
13. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain.
Herzberg U; Eliav E; Bennett GJ; Kopin IJ
Neurosci Lett; 1997 Jan; 221(2-3):157-60. PubMed ID: 9121688
[TBL] [Abstract][Full Text] [Related]
14. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats.
Ulugol A; Karadag HC; Ipci Y; Tamer M; Dokmeci I
Neurosci Lett; 2004 Nov; 371(2-3):167-70. PubMed ID: 15519750
[TBL] [Abstract][Full Text] [Related]
15. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system.
Palazzo E; de Novellis V; Petrosino S; Marabese I; Vita D; Giordano C; Di Marzo V; Mangoni GS; Rossi F; Maione S
Eur J Neurosci; 2006 Oct; 24(7):2011-20. PubMed ID: 17040473
[TBL] [Abstract][Full Text] [Related]
16. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve.
Costa B; Trovato AE; Colleoni M; Giagnoni G; Zarini E; Croci T
Pain; 2005 Jul; 116(1-2):52-61. PubMed ID: 15936882
[TBL] [Abstract][Full Text] [Related]
17. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
18. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
19. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat.
Dyson A; Peacock M; Chen A; Courade JP; Yaqoob M; Groarke A; Brain C; Loong Y; Fox A
Pain; 2005 Jul; 116(1-2):129-37. PubMed ID: 15936883
[TBL] [Abstract][Full Text] [Related]
20. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.
Bujalska M
Pharmacology; 2008; 82(3):193-200. PubMed ID: 18810243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
